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Abstract
Observer-driven pattern recognition is the standard for interpretation of medical images. To achieve global parity in
interpretation, semi-quantitative scoring systems have been developed based on observer assessments; these are
widely used in scoring coronary artery disease, the arthritides and neurological conditions and for indicating the
likelihood of malignancy. However, in an era of machine learning and artificial intelligence, it is increasingly desirable
that we extract quantitative biomarkers from medical images that inform on disease detection, characterisation,
monitoring and assessment of response to treatment. Quantitation has the potential to provide objective decision-
support tools in the management pathway of patients. Despite this, the quantitative potential of imaging remains
under-exploited because of variability of the measurement, lack of harmonised systems for data acquisition and
analysis, and crucially, a paucity of evidence on how such quantitation potentially affects clinical decision-making and
patient outcome. This article reviews the current evidence for the use of semi-quantitative and quantitative biomarkers
in clinical settings at various stages of the disease pathway including diagnosis, staging and prognosis, as well as
predicting and detecting treatment response. It critically appraises current practice and sets out recommendations for
using imaging objectively to drive patient management decisions.
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Key points
 Biomarkers derived from medical images inform on
disease detection, characterisation and treatment
response.
 Quantitative imaging biomarkers have potential to
provide objective decision-support tools in the
management pathway of patients.
 Measurement variability needs to be understood and
systems for data acquisition and analysis harmonised
before using quantitative imaging measurements to
drive clinical decisions.
Introduction
Interpretation of medical images relies on visual assess-
ment. Accumulated and learnt knowledge of anatomical
and physiological variations determines recognition of
appearances that are within “normal limits” and allows a
pathological change in appearances outside these limits
to be identified. Observer-driven pattern recognition
dominates the way that imaging data are used in routine
clinical practice (Fig. 1). A semi-quantitative approach to
image analysis has been advocated in various scenarios.
These use observer-based categorical scoring systems to
classify images according to the presence or absence of
certain features. Examples used widely in healthcare for
clinical decision-making include reporting and data sys-
tems (RADS) [1, 2]. Increasingly, however, advancement
in standardisation efforts, applications of analysis tech-
niques to extract quantitative information and machine
and deep learning techniques are transforming how
medical images may be exploited.
In some clinical scenarios, automated quantitation
may be more objective and accurate than manual assess-
ment; thresholds can be applied above or below which a
disease state is recognised and subsequent changes inter-
preted as clinically relevant [3]. Unlike biomaterials, im-
ages potentially can be transferred worldwide easily,
cheaply and quickly for biomarker extraction in an auto-
mated, reproducible and blinded manner. Nevertheless,
despite the substantial advantages of quantitation, very
few quantitative imaging biomarkers are used in clinical
decision-making due to several obstacles. Harmonisation
of data acquisition and analysis is non-trivial. Lack of
international standards without routine quality assur-
ance (QA) and quality control (QC) processes results in
poorly validated quantitative biomarkers that are subject
to errors in interpretation [4–6]. This has profound im-
plications for diagnosis (correct interpretation of the
presence of the disease state) [7] and treatment deci-
sion-making (based on interpretation of response vs
non-response) [8] and reduces the validity of combin-
ation biomarkers derived from hybrid (multi-modality)
imaging systems. The imaging community needs to en-
gage in delivering high-quality data for quantification
and adoption of machine learning to ultimately exploit
Fig. 1 Schematic of questions requiring decisions (red boxes), imaging assessments (grey boxes), the results of the imaging assessments (blue
ovals) and the management decisions they potentially influence (green boxes)
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quantitative imaging information for clinical decision-
making [9]. This manuscript describes the current evi-
dence and future recommendations for using semi-
quantitative or quantitative imaging biomarkers as deci-
sion-support tools in clinical trials and ultimately in rou-
tine clinical practice.
Validated imaging biomarkers currently used to
support clinical decision-making
The need for absolute quantitation (versus semi-quanti-
tative assessment) in decision-making should be clearly
established. Absolute quantitation is demanding and re-
source intensive because hardware and software differ-
ences across centres and instrumentation and their
evolution impact the quality of quantified data. Rigorous
on-going QA and QC are essential to support the valid-
ity and clinically acceptable repeatability of the measure-
ment, and efforts are on-going within RSNA and the
ESR and other academic societies. Critically also, defini-
tive thresholds to confidently separate normal from
pathological tissues based on absolute quantitative met-
rics often do not have wide applicability or acceptance.
Semi-quantitative scoring systems
Semi-quantitative readouts of scores based on an obser-
ver-recognition process are widely used because visual
interpretation often has proven adequate and is linked
to outcome. For example, MRI scoring systems for grad-
ing hypoxic-ischaemic injury in neonates using a com-
bination of T1-weighted (T1W) imaging, T2-weighted
(T2W) imaging and diffusion-weighted imaging (DWI)
have shown that higher post-natal grades were associ-
ated with poorer neuro-developmental outcome [10]. In
cervical spondylosis, grading of high T2-weighted (T2W)
signal within the spinal cord has been related variably to
disease severity and outcome [11, 12]. In common dis-
eases such as osteoarthritis, where follow-up scans to as-
sess progression are vital in treatment decision-making,
such scoring approaches also are useful [13]; web-based
knowledge transfer tools using the developed scoring
systems indicate good agreement between readers with
both radiological and clinical background specialisms in
interpreting the T2W MRI data [14]. Similar analyses
have been extensively applied in diseases such as mul-
tiple sclerosis [15] and even to delineate the rectal wall
from adjacent fibrosis [16]. In cancer imaging, 18FDG
PET/CT studies use the Deauville scale (liver and medi-
astinum uptake as reference) as the standard for re-
sponse assessment in lymphoma [17]. Semi-quantitative
scoring systems also form the basis of the breast imaging
(BI)-RADS and prostate imaging (PI)-RADS systems in
breast and prostate cancer respectively. Their wide
adoption has led to spawning of similar classification
scores for liver imaging (LI)-RADS [18–20], thyroid
imaging (TI)-RADS [20] and bladder (vesicle imaging,
VI)-RADS [21] tumours. Multiparametric MRI scores
are also used for detection of recurrent gynaecological
malignancy [22] and grading of renal cancer [23]. Man-
ual assessment of lung nodule diameter and volume
doubling time have reached a wide acceptance in the de-
cision-making of incidental detection, screening [24] and
prediction of response [25]. These parameters might be
substituted or improved by artificial intelligence in the
near future [26].
Quantitative measures of size/volume
The simplest quantitative measure used routinely is size.
Size is linked to outcome in both non-malignant and
malignant disease [27]. Ventricular size on echocardiog-
raphy is robust and incorporated into large multicentre
trials [28, 29] and into routine clinical care. Left ven-
tricular ejection fraction (LVEF) is routinely extracted
from both ultrasound and MRI measurements. In in-
flammatory diseases such as rheumatoid arthritis, where
bone erosions are a central feature, assessment of the
volume of disease on high-resolution CT provides a sur-
rogate marker of disease severity [30] and is associated
with the degree of physical impairment and mortality
[31, 32]. Yet these methods remain to be implemented
in a clinical setting because intensive segmentation and
post-processing resources are required. In cancer stud-
ies, unidimensional measurements (RECIST1.0 and 1.1)
[27] are used for response because of the perceived ro-
bustness and simplicity of the measurement, although
reproducibility is variable [33], resulting in uncertainty
[34]. Although numerous studies have linked disease
volume to outcome over decades of research [35–38],
volume is not routinely documented in clinical reports
because of the need for segmentation of irregularly
shaped tumours. Volume is indicative of prognosis and
response, for example in cervix cancer where evidence is
strong [39]. In other cancer types, such as lung, meta-
bolic active tumour volume on PET has a profound link
to survival [40, 41]. Metabolic active tumour volume also
has proven to be a prognostic factor in several lymph-
oma studies [42] and is being explored as a biomarker
for response to treatment [43–45]. The availability of au-
tomated volume segmentation at the point of reporting
is essential for routine adoption.
Extractable quantitative imaging biomarkers with
potential to support clinical decision-making
Quantitative imaging biomarkers that characterise tissue
features (e.g. calcium, fat and iron deposition, cellularity,
perfusion, hypoxia, diffusion, necrosis, metabolism, lung
airspace density, fibrosis) can provide information that
characterises a disease state and reflects histopathology.
Multiple quantitative features can be incorporated into
deSouza et al. Insights into Imaging           (2019) 10:87 Page 3 of 16
algorithms for recognising disease and its change over
time (both natural course and in response to therapy).
This involves an informatics style approach with data
built from atlases derived from validated cases. Curation
of anatomical databases annotated according to disease
presence, phenotype and grade can then be used with
the clinical data to build predictive models that act as
decision-support tools. This has been proposed for brain
data [46] but requires a collection of good quality vali-
dated data sets, carefully archived and curated. Harnes-
sing the quantitative information contained in images
with rigorous processes for acquisition and analysis, to-
gether with deep-learning algorithms such as has been
demonstrated for brain ageing [47] and treatment re-
sponse [48], will provide a valuable decision-support
framework.
Ultrasound
Quantitation in ultrasound imaging has derived parameters
related to cardiac output (left ventricular ejection fraction),
tissue stiffness (elastography) and vascular perfusion (con-
trast-enhanced ultrasound) where parameters are related
to blood flow. Ultrasound elastography is an emerging
field; it has been shown to differentiate liver fibrosis [49],
benign and malignant breast and prostate masses and inva-
sive and intraductal breast cancers [50, 51]. It also has been
explored for quantifying muscle stiffness in Parkinson’s dis-
ease [52], where low interobserver variation and significant
differences in Young’s modulus between mildly symptom-
atic and healthy control limbs make it a useful assessment
tool. Furthermore, it has shown acceptable inter-frame co-
efficient of variation for identifying unstable coronary pla-
ques [53]. Blood flow quantified by power Doppler has
potential as a bedside test for intramuscular blood flow in
the muscular dystrophies [54]. Quantified parameters peak
intensity (PI), mean transit time (MTT) and time to peak
(TTP) are available from contrast-enhanced ultrasound,
but rarely used because of competing studies with CT and
MRI that also capture morphology.
CT
CT biomarkers are dependent on a single biophysical par-
ameter, differential absorption of X-rays due to differences
in tissue density, either on unenhanced scans or following
administration of iodine-based contrast agent, which in-
creases X-ray absorption in highly perfused tissues. Other
developments have utilised tissue density as a parameter
in multicentre trials for quantification of emphysema
(COPDGene and SPIROMICS) [55–57] and interstitial
pulmonary fibrosis (IPF-NET) [58] and for assessment of
obstructive (reversible) airways disease [59, 60]. The stud-
ies have made use of various open source and bespoke re-
search software tools, but generally, these imaging-based
biomarkers have been used to guide treatment [61, 62]
and demonstrated direct correlation with outcomes and
functional parameters [63]. Drawbacks include poor
standardisation of imaging protocols (voltage, slice thick-
ness, respiration, I.V. contrast, kernel size) and post-pro-
cessing software [64], although many of these issues have
been resolved using phantom quality assurance and speci-
fied imaging procedures for every CT system used in these
studies [65, 66]. Standardisation of instrumentation would
simplify comparability between centres and enable long-
term data acquisition consistency even after scanner up-
dates [66]. In cardiac imaging, tissue density biomarkers
using coronary artery calcium scoring have been exten-
sively applied in large studies evaluating cardiac risk [67]
and luminal size on coronary angiography used in out-
come studies [68, 69]. Dual-energy CT quantifies iodine
concentration directly and is being investigated for charac-
terising pulmonary nodules and pleural tumours [70, 71].
MR including multiparametric data
MRI is more versatile than US and CT because it can be
manipulated to derive a number of parameters based on
multiple intrinsic properties of tissue (including T1- and
T2 relaxation times, proton density, diffusion, water-fat
fraction) and how these are altered in the presence of
other macromolecules (e.g. proteins giving rising to
magnetisation transfer and chemical exchange transfer
effects) and externally administered contrast agents
(Gadolinium chelates). Perfusion metrics have also been
derived with arterial spin labelling, which does not re-
quire externally administered agents [72]. The apparent
diffusion coefficient (ADC) is the most widely used
metric in oncology for disease detection [73, 74], prog-
nosis [75] and response evaluation [76, 77]. Post-pro-
cessing methods to derive absolute quantitation are
extensively debated [78, 79], but the technique is robust
with good reproducibility in multicentre, multivendor
trials across tumour types [80]. Refinements to model
intravascular incoherent motion (IVIM) and diffusion
kurtosis are currently research tools. In cardiovascular
MRI, there is a growing interest in quantifying T1 relax-
ation time, rather than just relying on its effect on image
contrast; when combined with the use of contrast agents,
T1 mapping allows investigation of interstitial remodel-
ing in ischaemic and non-ischaemic heart disease [81].
T1 values are useful to distinguish inflammatory pro-
cesses in the heart [82], multiple sclerosis in the central
nervous system [83], iron and fat content in the liver
[84, 85] and adrenal [86], which correlates with fibrosis
scores on histology [87]. Multiparametric MRI bio-
markers (T1 and proton density fat fraction) achieve a >
90% AUC for differentiating patients with significant
liver fibrosis and steatosis on histology [88] and are be-
ing supplemented by measurements of tissue stiffness
(MR elastography) where a measurement repeatability
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Table 1 Imaging biomarkers for disease detection (semi-quantitative and quantitative) with examples of current evidence for their
use that would support decision-making
Disease detection
Biomarker SemiQ/
Q
Disease Question
answered
Utility of biomarker Data from Potential decision
for
Non-
malignant
disease
LVEF-US
LVEF-MRI
Q Cardiac
function
[28, 29]
Cardiac
function
Cardiac
output
Cardiac
output
ICC US 0.72, single centre
sensitivity 69% [29]
ICC MRI 0.86,correlation of
MRI and cineventriculography
0.72 [99]
Single
centre US
Multicentre
MRI [99, 100]
Inotropes
Inotropes
Renal volume-
US, CT, MRI
Q Renal failure Mass of
parenchyma
ICC on US 0.64–0.86 [101]
Correlation of US with CT
0.76–0.8 [102]
Interobserver reproducibility
on MRI 87–88% [103]
Single centre Renal replacement,
safety and toxicity of
other pharmaceuticals
Young’s modulus
on elastography-
US
Q Thyroid [104],
breast [50]
and prostate
cancer [51]
Parkinson’s
disease
Tumour
presence
Muscle
stiffness
Thyroid sensitivity 80%,
specificity 95% [104]
Breast AUC 0.898 for
conventional US, 0.932
for shear wave elastography,
and 0.982 for combined
data [105]
Prostate sensitivity 0.84,
spec 0.84 [51]
Thyroid,
breast:
single
centre
Prostate
meta-analysis
Treatment with
surgery/radiotherapy/
chemotherapy
Lung tissue
density
Q Emphysema
[106, 107] and
fibrosis [58]
Airways
obstruction,
interstitial
lung disease
present
Emphysema (density
assessment) influences
BODE (body mass index,
airflow obstruction, dyspnea
and exercise capacity) index.
Odds ratio of interstitial lung
abnormalities for reduced lung
capacity 2.3
Multicentre
Single centre
Surgery, valve and
drug treatment
Fibrosis and
ground-glass
index on CT
lung
SQ Idiopathic
lung fibrosis
Development of
inflammation
and fibrosis
Mortality predicted by
pulmonary vascular volume
(HR 1.23 (1.08–1.40), p = 0.001)
and honeycombing (HR 1.18
(1.06–1.32), p = 0.002) [108]
Single centre Drug treatment
ADC/pCT SQ Ischaemic
stroke
Presence of
salvageable
tissue versus
infarct core
Measure of infarct core/
penumbra used for patient
stratification for research [109]
Planned
multicentre
Treatment
Malignant
disease
Lung RADS,
PanCan, NCCN
criteria [110, 111]
SQ Lung nodules Risk of
malignancy
AUC for malignancy
0.81–0.87 [110]
Multicentre Time period of
follow-up or surgery
CT blood flow,
perfusion,
permeability
metrics
Q Malignant
neck lymph
nodes
Hepatocellular
cancer
Tumour
presence
Sensitivity 0.73, specificity
0.70 [112]
AUC 0.75, sensitivity 0.79,
specificity 0.75 [113]
Single centre
Single centre
Staging and
management
(surgery, radiotherapy
or chemotherapy)
BI-RADS [114]
PI-RADS [115]
LI-RADS [116]
SQ Cancer Risk of
malignancy
PPV: BI-RADS0 14.1 %,
BI-RADS4 39.1 % and
BI-RADS5 92.9 %
PI-RADS2 pooled
sensitivity 0.85,
pooled specificity 0.71
Pooled sensitivity for
malignancy 0.93
Dutch breast
cancer
screening
programme
Meta-analysis
Systematic
review
Staging and
management
stratification
(surgery,
radiotherapy,
chemotherapy,
combination)
ADC Q Cancer [117]
Liver lesions
[118]
Prostate
cancer [119]
Tumour
presence
Liver AUC 0.82–0.95
Prostate AUC 0.84
Single centre
Single centre
Staging and
management
stratification
(surgery,
radiotherapy,
chemotherapy,
combination)
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coefficient of 22% has been demonstrated in a metaana-
lysis [89]. Chemical exchange saturation transfer (CEST)
MRI interrogates endogenous biomolecules with amide,
amine and hydroxyl groups; exogenous CEST agents
such as glucose provide quantitative imaging biomarkers
of metabolism and perfusion. Quantitative CEST im-
aging shows promise in assessing cerebral ischaemia
[90], lymphedema [91], osteoarthritis [92] and metabol-
ism/pH of solid tumours [93]. However, the small signal
requires higher field strength acquisition and substantial
post-processing.
Positron emission tomography (PET)-SUV metrics
Quantitation of 18FDG PET/CT studies is mainly per-
formed by standardised uptake values (SUVs), although
other metrics such as metabolic active tumour volume
(MATV) and total lesion glycolysis are being introduced
in studies and the clinic [94, 95]. The most frequently
used metric to assess the intensity of FDG accumulation
in cancer lesions is, however, still the maximum SUV.
SUV represents the tumour tracer uptake normalised for
injected activity per kilogram body weight. SUV and any
of the other PET quantitative metrics are affected by
technical (calibration of systems, synchronisation of
clocks and accurate assessment of injected 18FDG activ-
ity), physical (procedure, methods and settings used for
image acquisition, image reconstruction and quantitative
image analysis) and physiological factors (FDG kinetics
and patient biology/physiology) [96]. To mitigate these
factors, guidelines have been developed in order to stand-
ardise imaging procedures [96, 97] and to harmonise
PET/CT system performance at a European level [97, 98].
Newer targeted PET agents are only assessed qualitatively
on their distribution (Table 1).
Radiomic signature biomarkers
Radiomics describes the extraction and analysis of quan-
titative features from radiological images. The assump-
tion is that radiomic features reflect pathophysiological
processes expressed by other “omics”, such as genomics,
transcriptomics, metabolomics and proteomics [128].
Hundreds to thousands of radiomic features (mathemat-
ical descriptors of texture, heterogeneity or shape) can
be extracted from a region or volume of interest (ROI/
VOI), derived manually or semi-automatically by a hu-
man operator, or automatically by a computer algorithm.
The radiomic “signature” (summary of all features) is ex-
pected to be specific for a given patient, patient group,
Table 1 Imaging biomarkers for disease detection (semi-quantitative and quantitative) with examples of current evidence for their
use that would support decision-making (Continued)
Disease detection
Biomarker SemiQ/
Q
Disease Question
answered
Utility of biomarker Data from Potential decision
for
Dynamic contrast
enhanced metrics
(Ktrans, Kep, blood
flow, Ve)
Q Liver tumour
Recurrent
glioblastoma
Hepatocellular cancer
AUC 0.85, sensitivity 0.85,
specificity 0.81 [113]
Brain- KtransAccuracy
86% [120]
Single centre
Single centre
Further treatment
18FDG SUV Q Cancer
Sarcoma [121]
Lung cancer
[105]
Tumour
presence
Sarcoma—sensitivity
0.91, specificity 0.85,
accuracy 0.88
Lung—sensitivity 0.68
to 0.95 depending on
histology
Meta-analysis
Meta-analysis
Staging and
management
stratification
(surgery,
radiotherapy,
chemotherapy,
combination)
Targeted radionuclides
[122]In-octreotide
[123]
[68]Ga DOTATOC and
[68]Ga DOTATATE
[124, 125] [68]Ga
PSMA [4]
Non-Q Cancer Tumour
presence
Sensitivity 97% and
specificity 92% for
octreotide [126]
Sensitivity 100% and
specificity 100% for
PSMA [127]
Single centre
Single centre
Validation remains
difficult because of
biopsying multiple
positive sites.
Biomarkers used visually in the clinic are given in italics, and those that are used quantitatively are in bold
Abbreviations: ADC apparent diffusion coefficient, APT amide proton transfer, AUC area under curve, BI-RADS breast imaging reporting and data systems, CBV
cerebral blood volume, CoV coefficient of variation, CR complete response, CT computerised tomography, DCE dynamic contrast enhanced, DFS disease-free
survival, DOTATOC DOTA octreotitide, DOTATATE DOTA octreotate, DSC dynamic susceptibility contrast, ECG electro cardiogram, FDG fluorodeoxyglucose, FLT
fluoro thymidine, HR hazard ratio, HU Hounsfield unit, ICC intraclass correlation, IQR interquartile range, LVEF left ventricular ejection fraction, MRF magnetic
resonance fingerprinting, MRI magnetic resonance imaging, MTR magnetisation transfer ratio, NCCN National Comprehensive Cancer Network, OS overall survival,
pCT perfusion computerised tomography, PERCIST positron emission tomography response criteria in solid tumours, PD progressive disease, PFS progression-free
survival, PPV positive predictive value, PI-RADS prostate imaging reporting and data systems, PR partial response, PSMA prostate-specific membrane antigen, RECIL
response evaluation in lymphoma, RECIST response evaluation criteria in solid tumours, ROC receiver operating characteristic, SD stable disease, SUV standardised
uptake value, SWE shear wave elastography, US ultrasound
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Table 2 Imaging biomarkers for disease characterisation (semi-quantitative and quantitative) with examples of current evidence for
their use that would support decision-making
Biomarker SemiQ/
Q
Disease Question answered Utility of biomarker Data from Potential decision
for
Non-
malignant
disease
Young’s
modulus
Q Coronary
plaques [53]
Risk of rupture Reproducibility CoV 22% vessel wall,
19% in plaque. AUC for focal neurology
Youngs modulus + degree = 0.78
Single
centre
Stenting, coronary
bypass surgery
Plaque
density,
vessel
luminal
diameter
Q Coronary
artery
stenosis
Risk of plaque
rupture; risk of
significant cardiac
ischaemia, infarction,
death
No luminal narrowing but with
coronary artery calcium (CAC) score > 0
had a 5-year mortality HR 1.8
compared with those whose CACS = 0.
No luminal narrowing but CAC ≥ 100
had mortality risks similar to individuals
with non-obstructive coronary artery
disease [138]
CT angiography significantly better at
predicting events than stress echo/ECG
[68]
Coronary death/non-fatal myocardial
infarction was lower in patients with
stable angina receiving CT angiography
than in the standard-care group (HR =
0.59) [69]
Multicentre
Multicentre
Multicentre
Statins, stenting,
coronary bypass
surgery
18F-Na SQ Aortic valve
disease
Coronary
plaque [139]
Acute events
from abdominal
aortic aneurysm
Valve stenosis
present
Likelihood of plaque
rupture
Likelihood of
aneurysm rupture
Reproducibility NaF uptake 10% [140]
Baseline 18F-NaF uptake correlated
closely with the change in calcium
score at 1 year [141]
18F-NaF uptake (maximum tissue-to-
background ratio 1·90 [IQR 1.61–2.17])
associated with ruptured plaques and
those with high-risk features [142]
Aneurysms in the highest tertile of 18F-
NaF uptake expanded 2.5× more
rapidly than those in the lowest tertile
and were 3× more likely to rupture
[143]
Single
Multicentre
Coronary stenting,
aneurysm stenting
MTR Q Multiple
sclerosis
Disease progression MTR significantly correlates with T2
lesion volume [144]
Grey matter MTR histogram peak
height and average lesion MTR
percentage change after 12 months
independent predictors of disability
worsening at 8 years [145]
Change in brain MTR specificity 76.9%
and PPV 59.1% for Expanded Disability
Status Scale score deterioration [146]
Multicentre
Single
centre
Single
centre
Timing of
therapeutic
intervention
Malignant
disease
18FDG-SUV Q Cancer
Oesophageal
cancer
Good or poor
prognosis tumour in
terms of PFS and OS
Wide variation between individuals and
tumours [147]
Oesophageal cancer HR 1.86 for OS,
2.52 for DFS [148]
Meta-
analysis
Neoadjuvant or
adjuvant therapy
or treatment
modality
combinations
18FLT-SUV Q Cancer High proliferative
activity present
Sizeable overlap in values with normal
proliferating tissues [75]
Review of
data from
single
centre
studies
Neoadjuvant or
adjuvant therapy
or treatment
modality
combinations
ADC
MRF (ADC,
T1 and T2)
Q
Q
Q
Cancer,
correlates
with tumour
grade
Risk of recurrence or
metastasis
Area under ROC, sensitivity and
specificity of nADCmean for G3
intrahepatic cholangiocarcinoma versus
G1+G2 were 0.71, 89.5% and 55.5%
[149]
“Unfavourable” ADC in cervix cancer
predictive of disease-free survival (HR
1.55) [150]
ADC and T2 together give AUC of 0.83
for separating high- or intermediate-
grade from low-grade prostate cancer
Single
centre
Meta-
analysis
Single
centre
Need of biopsy or
other invasive
diagnosis
Neoadjuvant or
adjuvant therapy
Decision for
radical treatment
or active
surveillance
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tissue or disease [129, 130]: it depends on the type of
imaging data (CT, MRI, PET) and is influenced by image
acquisition parameters (e.g. resolution, reconstruction
algorithm, repetition/echo times for MRI), hardware
(e.g. scanner model, coils), VOI/ROI segmentation [131]
and image artifacts.
Unlike biopsies, radiomic analyses, although not tissue
specific, capture heterogeneity across the entire volume
[132], potentially making them more indicative of ther-
apy response, resistance and survival. They may be
therefore better suited to decision support in terms of
treatment selection and risk stratification. Current radio-
mics research in X-ray mammography [133] and cross-
sectional imaging (lung, head and neck, prostate, GI
tract, brain) has shown promising results [134], leading
to extrapolation in non-malignant disease. Image quality
optimisation and standardisation of data acquisition are
mandatory for widespread application. At present, indi-
vidual research groups derive differing versions of a
similar signature and there is a tendency to change the
signature from study to study. Since radiomic signatures
are typically multi-dimensional data, they are an ideal in-
put for advanced machine learning techniques, such as
artificial neural networks, especially when big multi-
centric datasets are available. Early reports from multi-
centre trials indicate that reproducibility of feature
Table 2 Imaging biomarkers for disease characterisation (semi-quantitative and quantitative) with examples of current evidence for
their use that would support decision-making (Continued)
Biomarker SemiQ/
Q
Disease Question answered Utility of biomarker Data from Potential decision
for
[151]
DSC-MRI SQ
(rCBV)
Brain cancer Grading glioma AUC = 0.77 for discriminating glioma
grades II and III [152]
Meta-
analysis
Type and time of
intervention/
treatment
APT Q Glioma Proliferation APT correlates with tumour grade and
Ki67 index [153]
Single
centre
Therapeutic
strategies
DCE-CT
parameters
Blood flow,
permeability
Q Rectal cancer
Lung cancer
Blood flow 75% accuracy for detecting
rectal tumours with lymph node
metastases [154]
CT permeability predicted survival
independent of treatment in lung
cancer [155]
Single
centre
Single
centre
Surgical
dissection,
adjuvant
radiotherapy
Adjuvant therapy
DCE-MRI
parameters
Q Cervix cancer
Endometrial
cancer
Rectal cancer
Breast cancer
Risk of recurrence or
metastasis, survival
Tumour volume with increasing signal
is a strong independent prognostic
factor for DFS and OS in cervical cancer
[156]
Low tumour blood flow and low rate
constant for contrast agent
intravasation (kep) associated with high-
risk histological subtype in endometrial
cancer [157]
Ktrans, Kep and Ve significantly higher in
rectal cancers with distant metastasis
[158]
Ktrans, iAUCqualitative and ADC predict
low-risk breast tumors (AUC of
combined parameters 0.78)
Single
centre
Single
centre
Single
centre
Single
centre
Neoadjuvant,
adjuvant or
multimodality
treatment
strategies
Radiomic
signature
[159]
Q Multiple
tumour types
[160, 161]
Tumour with good
or poor prognosis
Data endpoints, feature selection
techniques and classifiers were
significant factors in affecting predictive
accuracy in lung cancer [162]
Radiomic signature (24 selected
features) is significantly associated with
LN status in colorectal cancer [163]
Single
centre
Single
centre
Neoadjuvant or
adjuvant
treatment,
immunotherapy
Lymph node
dissection,
adjuvant
treatment
Biomarkers used visually in the clinic are given in italics, and those that are used quantitatively are in bold
Abbreviations: ADC apparent diffusion coefficient, APT amide proton transfer, AUC area under curve, BI-RADS breast imaging reporting and data systems, CBV
cerebral blood volume, CoV coefficient of variation, CR complete response, CT computerised tomography, DCE dynamic contrast enhanced, DFS disease-free
survival, DOTATOC DOTA octreotitide, DOTATATE DOTA octreotate, DSC dynamic susceptibility contrast, ECG electro cardiogram, FDG fluorodeoxyglucose, FLT
fluoro thymidine, HR hazard ratio, HU Hounsfield unit, ICC intraclass correlation, IQR interquartile range, LVEF left ventricular ejection fraction, MRF magnetic
resonance fingerprinting, MRI magnetic resonance imaging, MTR magnetisation transfer ratio, NCCN National Comprehensive Cancer Network, OS overall survival,
pCT perfusion computerised tomography, PERCIST positron emission tomography response criteria in solid tumours, PD progressive disease, PFS progression-free
survival, PPV positive predictive value, PI-RADS prostate imaging reporting and data systems, PR partial response, PSMA prostate-specific membrane antigen, RECIL
response evaluation in lymphoma, RECIST response evaluation criteria in solid tumours, ROC receiver operating characteristic, SD stable disease, SUV standardised
uptake value, SWE shear wave elastography, US ultrasound
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Table 3 Imaging biomarkers for disease response assessment (semi-quantitative and quantitative) with examples of current
evidence for their use that would support decision-making
Biomarker SemiQ/
Q
Disease Question answered Utility of biomarker Data from Potential
decision for
Non-
malignant
disease
Volumetric high
resolution CT density
(quantitative interstitial
lung disease, QILD)
Q Scleroderma Response to
cyclophosphamide
24-month changes in QILD
scores in the whole lung
correlated significantly
24-month changes in
forced vital capacity
(ρ = − 0.37), diffusing
capacity (ρ = − 0.22)
and breathlessness
(ρ = − 0.26) [164]
Single
centre
Continue,
change or
stop treatment
Left Ventricular
ejection fraction LVEF
Q Pulmonary
hypertension
Myocardial
ischaemia/
infarction
Right and left
cardiac sufficiency
Improvement in
cardiac function
Increases in 6-min walk
distance were significant
correlated with change in
right ventricular ejection
fraction and left ventricular
end-diastolic volume [165]
Monitoring cardiac
function [166]
Multicentre
Multicentre
Continue,
change or
stop treatment
Malignant
disease
RECIST/morphological
volume
Q Cancer Response Current guidelines for
response assessment [167]
Multicentre Continue,
change or
stop treatment
PERCIST/metabolic
volume [168]
Q Cancer Response Current guidelines for
response assessment
Multicentre Continue,
change or
stop treatment
Scoring systems for
disease burden
SQ Multiple
sclerosis
Rheumatoid
arthritis
Reduction in
disease burden
Effects on MRI lesions over
6–9 months predict the
effects on relapses at
12–24 months) [169]
International consensus on
scoring system [170]
Meta-
analysis
Review
Continue,
change or
stop therapy
DSC-MRI SQ
(rCBV)
Brain cancer Differentiation of
treatment effects
and tumour
progression
In 2 meta-analyses MRI had
high pooled sensitivities and
specificities: 87% (95% CI,
0.82–0.91) to 90% (95% CI,
0.85-0.94) sensitivity and 86%
(95% CI, 0.77–0.91) to 88%
(95% CI, 0.83-0.92) specificity
[171, 172]
Meta-
analysis
Decision to
treat
18F FDG-SUVmax [173] Q Multiple
cancer types
Response
to therapy
Rectal cancer-pooled
sensitivity, 73%; pooled
specificity, 77%; pooled
AUC, 0.83 [174]
Intratreatment low SUVmax
(persistent low or decrease
of 18F-FDG uptake) predictive
of loco-regional control in
head and neck cancer [175]
Meta-
analysis
Meta-
analysis
Continue,
change or
stop therapy
Deauville or RECIL score
on 18F-FDG-PET
SQ Lymphoma CR, PR, SD or
PD [176]
Assessment of tumour burden
in lymphoma clinical trials can
use the sum of longest diameters
of a maximum of three target
lesions [177]
Multicentre Continue,
change or
stop therapy
Targeted agents
HER2
PSMA
SQ Breast cancer
[178]
Prostate cancer
[179]
Reduction in
tumour cells
expressing
these antigens
Tumour receptor specific
Effects of treatment on
receptor expression
Single
centre
studies,
review
Continue,
change or
stop therapy
ADC [117] SQ
Q
Rectal cancer
Breast cancer
Response to
neoadjuvant
chemotherapy
Response to
neoadjuvant
chemotherapy
Additional value in both the
prediction and detection of
(complete) response to therapy
compared with conventional
sequences alone [180]
After 12 weeks of therapy,
Review
Multicentre
Continue,
change or
stop therapy,
proceed to
surgery
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Table 3 Imaging biomarkers for disease response assessment (semi-quantitative and quantitative) with examples of current
evidence for their use that would support decision-making (Continued)
Biomarker SemiQ/
Q
Disease Question answered Utility of biomarker Data from Potential
decision for
change in ADC predicts
complete pathologic
response to neoadjuvant
chemotherapy (AUC = 0.61,
p = 0.013) [181]
CT perfusion/blood
flow
Q Oesophageal
cancer
Response to
chemoradiotherapy
Multivariate analysis
identified blood flow
as a significant
independent predictor
of response [182]
Single
centre
Further
treatment
DCE-MR parameters Q Multiple
cancer types
Response to
therapy
Particular benefit in
assessing therapy
response to
antiangiogenic
agents [183]
Review Change
therapeutic
strategy
CT density HU Q Gastrointestinal
stromal tumours
Response to
chemotherapy
Decrease in tumour
density of > 15% on
CT had a sensitivity
of 97% and a specificity
of 100% in identifying
PET responders versus
52% and 100% by
RECIST [184]
Continue,
change or
stop therapy
Biomarkers used visually in the clinic are given in italics, and those that are used quantitatively are in bold
Abbreviations: ADC apparent diffusion coefficient, APT amide proton transfer, AUC area under curve, BI-RADS breast imaging reporting and data systems, CBV cerebral
blood volume, CoV coefficient of variation, CR complete response, CT computerised tomography, DCE dynamic contrast enhanced, DFS disease-free survival, DOTATOC
DOTA octreotitide, DOTATATE DOTA octreotate, DSC dynamic susceptibility contrast, ECG electro cardiogram, FDG fluorodeoxyglucose, FLT fluoro thymidine, HR hazard
ratio, HU Hounsfield unit, ICC intraclass correlation, IQR interquartile range, LVEF left ventricular ejection fraction, MRF magnetic resonance fingerprinting, MRI magnetic
resonance imaging, MTR magnetisation transfer ratio, NCCN National Comprehensive Cancer Network, OS overall survival, pCT perfusion computerised tomography,
PERCIST positron emission tomography response criteria in solid tumours, PD progressive disease, PFS progression-free survival, PPV positive predictive value, PI-RADS
prostate imaging reporting and data systems, PR partial response, PSMA prostate-specific membrane antigen, RECIL response evaluation in lymphoma, RECIST response
evaluation criteria in solid tumours, ROC receiver operating characteristic, SD stable disease, SUV standardised uptake value, SWE shear wave elastography, US ultrasound
Table 4 Recommendations for the use of quantitative imaging biomarkers as decision-support tools
Recommendation Current evidence Action needed
Consider need for quantitation
in relation to the decision being
made
Semi-quantitative imaging biomarkers are
successfully used in many clinical pathways.
• Classification systems retain a subjective element
that could benefit from standardisation and refinement.
• Development of automated and thresholding would
enable more quantitative assessments
Use validated IB methodology for
semi-quantitative and quantitative
measures
Many single and multicentre trials validating
quantitative imaging biomarkers with clinical
outcome now exist.
• Harmonisation of methodology
• Standardised reporting systems
Establish evidence on the use of
quantitation by inclusion into
clinical trials
Clinical trials are usually planned by non-imagers.
Integration of imaging biomarkers into trials is
dependent on what is available routinely to
non-imagers in the clinic, rather than exploiting
an imaging technique to its optimal potential.
• Inventory of imaging biomarkers accessible through
a web-based portal would inform the inclusion and
utilisation of imaging biomarkers within trials (The
European Imaging Biomarkers Alliance initiative).
• Certified biomarkers conforming to set standards
(Quantitative Imaging Biomarkers Alliance initiative)
Validate against pathology or
clinical outcomes to make
imaging a “virtual biopsy”
Several major databanks hold imaging and
clinical or pathology data
• CaBIG (USA)
• UK MRC Biobank (UK)
• German National Cohort Study (Germany)
• Large data collection for validation of imaging
and pathology
• Curation in imaging biobanks
Select appropriate quality
assured quantitative IB
Trials with embedded QA/QC procedures have
indicated good reproducibility of quantitative
imaging biomarkers (e.g. EU iMi QuIC:ConCePT
project)
• Ensure curation and archiving of longitudinal imaging
data with outcomes within trials
Open-source interchange kernel Low comparability between image-derived
biomarkers if hardware and software of
different manufacturers are used.
• Harmonisation of image acquisition and post-processing
over manufacturers
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selection is good when extracted from CT [135] as well
as MRI [136] data.
Selecting and translating appropriate imaging
biomarkers to support clinical decision-making
Automated quantitative assessments rather than scoring
systems are easier to incorporate into artificial
intelligence systems. For this, threshold values need to
be established and a probability function of the likeli-
hood of disease vs. no disease derived from the absolute
quantitation (e.g. bone density measurements) [137]. Al-
ternatively, ratios of values to adjacent healthy tissue can
be used to recognise disease. Similarly, for prognostic in-
formation, thresholds established from large databases
will define action limits for altering management based
on the likelihood of a good or poor outcome predicted
by imaging data. This will enable the clinical community
to move towards using imaging as a “virtual biopsy”.
The current evidence for use of quantitative imaging
biomarkers for diagnostic and prognostic purposes is
given in Tables 1 and 2 respectively.
For assessing treatment response (Table 3), the key
element in biomarker selection relates to the type of
treatment and expected pathological response. For non-
targeted therapies, tissue necrosis to cytotoxic agents is
expected, so biomarkers that read-out on increased free
water (CT Hounsfield units) or reduced cell density
(ADC) are most useful. With specific targeted agents
(e.g. antiangiogenics), specific biomarker read-outs (per-
fusion metrics by US, CT or MRI) are more appropriate
[185]. Both non-targeted and targeted agents shut down
tumour metabolism, so that in glycolytic tumours, FDG
metrics are exquisitely sensitive [186]. Distortion and
changes following surgery, or changes in the adjacent
normal tissue following radiotherapy [122], reduce quan-
titative differences between irradiated non-malignant
and residual malignant tissue, so must be taken into ac-
count [187]. In multicentre trials, it is also crucial to es-
tablish the repeatability of the quantitative biomarker
across multiple sites and vendor platforms for response
interpretation [4].
Advancing new quantitative imaging biomarkers
as decision-support tools to clinical practice
To become clinically useful, biomarkers must be rigorously
evaluated for their technical performance, reproducibility,
biological and clinical validity, and cost-effectiveness [6].
Table 4 gives current recommendations for use of quantita-
tive biomarkers as decision support tools.
Technical validation establishes whether a biomarker
can be derived reliably in different institutions (compar-
ability) and on widely available platforms. Provision
must be made if specialist hardware or software is re-
quired, or if a key tracer or contrast agent is not licensed
for clinical use. Reproducibility, a mandatory require-
ment, is very rarely demonstrated in practice [188] be-
cause inclusion of a repeat baseline study is resource
and time intensive for both patients and researchers.
Multicentre technical validation using standardised pro-
tocols may occur after initial biological validation (evi-
dence that known perturbations in biology alter the
imaging biomarker signal in a way that supports the
measurement characteristics assigned to the biomarker).
Subsequent clinical validation, showing that the same re-
lationships are observed in patients, may then occur in
parallel to multicentre technical validation.
Once a biomarker is shown to have acceptable tech-
nical, biological and clinical validation, a decision must
be made to qualify the biomarker for a specific purpose
or use. Increasingly, the role of imaging in the context of
other non-imaging biomarkers needs to be considered as
part of a multiparametric healthcare assessment. For ex-
ample, circulating biomarkers such as circulating tumour
DNA are often more specific at detecting disease but do
not localise or stage tumours. The integration of imaging
biomarkers with tissue and liquid biomarkers is likely to
replace many traditional and more simplistic approaches
to decision-support systems that are used currently.
The cost-effectiveness of a biomarker is increasingly im-
portant in financially restricted healthcare systems where
value-based care is increasingly considered [189]. How-
ever, the information may be derived from scans done as
part of the patients’ clinical work-up. Nevertheless, add-
itional imaging/image processing is expensive compared
to liquid- and tissue-based biomarkers. Costs can be off-
set against the cost saving from the unnecessary use of ex-
pensive but ineffective novel and targeted drugs. Health
economic assessment is therefore an important part of
translating a new biomarker into routine clinical practice.
In an era of artificial intelligence, where radiologists are
faced with an ever-increasing volume of digital data, it
makes sense to increase our efforts at utilising validated,
quantified imaging biomarkers as key elements in sup-
porting management decisions for patients.
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ADC: Apparent diffusion coefficient; APT: Amide proton transfer; AUC: Area
under curve; CBV: Cerebral blood volume; CEST: Chemical exchange
saturation transfer; CoV: Coefficient of variation; CR: Complete response;
CT: Computerised tomography; DCE: Dynamic contrast enhanced;
DFS: Disease-free survival; DOTATOC: DOTA octreotitide; DOTATATE: DOTA-
octreotate; DSC: Dynamic susceptibility contrast; DWI: Diffusion-weighted
imaging; ECG: Electrocardiogram; ESR: European Society of Radiology;
FDG: Fluorodeoxyglucose; FLT: Fluorothymidine; HR: Hazard ratio;
HU: Hounsfield unit; ICC: Intraclass correlation; IPF: Interstitial pulmonary
fibrosis; IQR: Interquartile range; LVEF: Left ventricular ejection fraction;
MATV: Metabolic active tumour volume; MRF: Magnetic resonance
fingerprinting; MRI: Magnetic resonance imaging; MTR: Magnetisation
transfer ratio; MTT: Mean transit time; NCCN: National Comprehensive Cancer
Network; OS: Overall survival; pCT: Perfusion computerised tomography;
PERCIST: Positron emission tomography response criteria in solid tumours;
PD: Progressive disease; PFS: Progression free survival; PPV: Positive predictive
deSouza et al. Insights into Imaging           (2019) 10:87 Page 11 of 16
value; PI: Peak intensity; PR: Partial response; PSMA: Prostate specific
membrane antigen; QA: Quality assurance; QC: Quality control;
RADS: Reporting and data systems (BI, breast imaging; LI, liver imaging; PI,
prostate imaging; TI, thyroid imaging; VI, vesicle imaging); RECIL: Response
evaluation in lymphoma; RECIST: Response evaluation criteria in solid
tumours; ROC: Receiver operating characteristic; ROI: Region of interest;
RSNA: Radiological Society of North America; SD: Stable disease;
SUV: Standardised uptake value; SWE: Shear wave elastography; TTP: Time to
peak; US: Ultrasound; VOI: Voxel of interest
Acknowledgements
This paper was reviewed and endorsed by the ESR Executive Council in
March 2019.
Authors’ contributions
All authors have contributed to the conception of the work, have drafted
the work and have approved the submitted final version of the manuscript.
Authors’ information
All authors are either past or current members of the European Biomarkers
Alliance subcommittee.
Funding
None declared for this work.
Availability of data and materials
Not applicable
Ethics approval and consent to participate
Not applicable
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Author details
1Cancer Research UK Imaging Centre, The Institute of Cancer Research and
The Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK.
2Ghent University Hospital, Ghent, Belgium. 3QUIBIM SL / La Fe Health
Research Institute, Valencia, Spain. 4Department of Radiology, University of
Freiburg, Freiburg im Breisgau, Germany. 5VU University Medical Center,
Amsterdam, The Netherlands. 6Hopital Européen Georges Pompidou, Paris,
France. 7University of Cambridge, Cambridge, UK. 8UCL Institute of
Neurology, London, UK. 9Universitätsklinik Heidelberg, Translational Lung
Research Center (TLRC), German Center for Lung Research (DZL), University
of Heidelberg, Im Neuenheimer Feld 156, 69120 Heidelberg, Germany.
10University of Wisconsin School of Medicine and Public Health, Madison, WI,
USA. 11Department of Radiology and Nuclear Medicine, Radboud University
Medical Center, Geert Grooteplein 10, 6525, GA, Nijmegen, The Netherlands.
12Medical University Vienna, Vienna, Austria. 13Department of Translational
Research, University of Pisa, Pisa, Italy. 14Division of Cancer Sciences,
University of Manchester, Manchester, UK. 15Hacettepe University Hospitals,
Ankara, Turkey. 16Linköpings Universitet, Linköping, Sweden. 17Department of
Radiology and Nuclear Medicine (Ne-515), Erasmus MC, PO Box 2040, 3000,
CA, Rotterdam, The Netherlands. 18Edinburgh Imaging, Queen’s Medical
Research Institute, Edinburgh Bioquarter, 47 Little France Crescent,
Edinburgh, UK. 19University Hospital Basel, Radiology and Nuclear Medicine,
University of Basel, Petersgraben 4, CH-4031 Basel, Switzerland. 20European
Society of Radiology, Am Gestade 1, 1010 Vienna, Austria.
Received: 3 May 2019 Accepted: 28 June 2019
References
1. Mercado CL (2014) BI-RADS update. Radiol Clin North Am. 52:481–487
2. Barentsz JO, Weinreb JC, Verma S et al (2016) Synopsis of the PI-RADS v2
guidelines for multiparametric prostate magnetic resonance imaging and
recommendations for use. Eur Urol. 69:41–49
3. Hosny A, Parmar C, Quackenbush J, Schwartz LH, Aerts HJWL (2018) Artificial
intelligence in radiology. Nat Rev Cancer. 18:500–510
4. Zacho HD, Nielsen JB, Afshar-Oromieh A et al (2018) Prospective comparison
of (68)Ga-PSMA PET/CT, (18)F-sodium fluoride PET/CT and diffusion weighted-
MRI at for the detection of bone metastases in biochemically recurrent
prostate cancer. Eur J Nucl Med Mol Imaging. 45:1884–1897
5. Boellaard R, Delgado-Bolton R, Oyen WJ et al (2015) FDG PET/CT: EANM
procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol
Imaging. 42:328–354
6. O'Connor JP, Aboagye EO, Adams JE et al (2017) Imaging biomarker
roadmap for cancer studies. Nat Rev Clin Oncol. 14:169–186
7. Zhuang M, Vallez Garcia D, Kramer GM et al (2018) Variability and
repeatability of quantitative uptake metrics in [(18)F]FDG PET/CT imaging of
non-small cell lung cancer: impact of segmentation method, uptake
interval, and reconstruction protocol. J Nucl Med 60:600–607
8. Barrington SF, Kirkwood AA, Franceschetto A et al (2016) PET-CT for staging
and early response: results from the Response-Adapted Therapy in Advanced
Hodgkin Lymphoma study. Blood. 127:1531–1538
9. Hosny A, Parmar C, Quackenbush J, Schwartz LH, Aerts HJWL (2018) Artificial
intelligence in radiology. Nat Rev Cancer 18:500–510
10. Trivedi SB, Vesoulis ZA, Rao R et al (2017) A validated clinical MRI injury
scoring system in neonatal hypoxic-ischemic encephalopathy. Pediatric
radiology. 47:1491–1499
11. Machino M, Ando K, Kobayashi K et al (2018) Alterations in intramedullary
T2-weighted increased signal intensity following laminoplasty in cervical
spondylotic myelopathy patients: comparison between pre- and
postoperative magnetic resonance images. Spine (Phila Pa 1976). 43:1595–
1601
12. Chen CJ, Lyu RK, Lee ST, Wong YC, Wang LJ (2001) Intramedullary high
signal intensity on T2-weighted MR images in cervical spondylotic
myelopathy: prediction of prognosis with type of intensity. Radiology. 221:
789–794
13. Khanna D, Ranganath VK, Fitzgerald J et al (2005) Increased radiographic
damage scores at the onset of seropositive rheumatoid arthritis in older
patients are associated with osteoarthritis of the hands, but not with more
rapid progression of damage. Arthritis Rheum. 52:2284–2292
14. Jaremko JL, Azmat O, Lambert RGW et al (2017) Validation of a knowledge
transfer tool according to the OMERACT filter: does web-based real-time
iterative calibration enhance the evaluation of bone marrow lesions in hip
osteoarthritis? J Rheumatol. 44:1713–1717
15. Molyneux PD, Miller DH, Filippi M et al (1999) Visual analysis of serial T2-
weighted MRI in multiple sclerosis: intra- and interobserver reproducibility.
Neuroradiology. 41:882–888
16. Stollfuss JC, Becker K, Sendler A et al (2006) Rectal carcinoma: high-spatial-
resolution MR imaging and T2 quantification in rectal cancer specimens.
Radiology. 241:132–141
17. Barrington SF, Mikhaeel NG, Kostakoglu L et al (2014) Role of imaging in the
staging and response assessment of lymphoma: consensus of the
International Conference on Malignant Lymphomas Imaging Working
Group. J Clin Oncol 32:3048–3058
18. Chernyak V, Fowler KJ, Kamaya A et al (2018) Liver Imaging Reporting and
Data System (LI-RADS) Version 2018: imaging of hepatocellular carcinoma in
at-risk patients. Radiology 289:816–830
19. Elsayes KM, Hooker JC, Agrons MM et al (2017) 2017 version of LI-RADS for
CT and MR imaging: an update. Radiographics. 37:1994–2017
20. Tessler FN, Middleton WD, Grant EG et al (2017) ACR thyroid imaging,
reporting and data system (TI-RADS): white paper of the ACR TI-RADS
committee. J Am Coll Radiol. 14:587–595
21. Panebianco V, Narumi Y, Altun E et al (2018) Multiparametric Magnetic
Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical
Imaging-Reporting And Data System). Eur Urol. 74:294–306
22. Kitajima K, Tanaka U, Ueno Y et al (2015) Role of diffusion weighted
imaging and contrast-enhanced MRI in the evaluation of intrapelvic
recurrence of gynecological malignant tumour. PLoS One. 10:e0117411
23. Cornelis F, Tricaud E, Lasserre AS et al (2015) Multiparametric magnetic
resonance imaging for the differentiation of low and high grade clear cell
renal carcinoma. Eur Radiol. 25:24–31
24. Martin MD, Kanne JP, Broderick LS, Kazerooni EA, Meyer CA (2017) Lung-
RADS: pushing the limits. Radiographics. 37:1975–1993
25. Sabra MM, Sherman EJ (2017) Tumour volume doubling time of pulmonary
metastases predicts overall survival and can guide the initiation of
deSouza et al. Insights into Imaging           (2019) 10:87 Page 12 of 16
multikinase inhibitor therapy in patients with metastatic, follicular cell-
derived thyroid carcinoma. Cancer 123:2955–2964
26. Kadir T, Gleeson F (2018) Lung cancer prediction using machine learning
and advanced imaging techniques. Transl Lung Cancer Res. 7:304–312
27. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation
criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer
45:228–247
28. Yao GH, Zhang M, Yin LX et al (2016) Doppler Echocardiographic Measurements
in Normal Chinese Adults (EMINCA): a prospective, nationwide, and multicentre
study. Eur Heart J Cardiovasc Imaging. 17:512–522
29. Elgendy A, Seppelt IM, Lane AS (2017) Comparison of continous-wave
Doppler ultrasound monitor and echocardiography to assess cardiac output
in intensive care patients. Crit Care Resusc 19:222–229
30. Figueiredo CP, Kleyer A, Simon D et al (2018) Methods for segmentation of
rheumatoid arthritis bone erosions in high-resolution peripheral quantitative
computed tomography (HR-pQCT). Semin Arthritis Rheum. 47:611–618
31. Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL (2001)
The relationship between disease activity, joint destruction, and functional
capacity over the course of rheumatoid arthritis. Arthritis Rheum. 44:2009–2017
32. Ødegård S1, Landewé R, van der Heijde D, Kvien TK, Mowinckel P, Uhlig T
(2006) Association of early radiographic damage with impaired physical
function in rheumatoid arthritis: a ten-year, longitudinal observational study
in 238 patients. Arthritis Rheum. 54:68–75
33. Marcus CD, Ladam-Marcus V, Cucu C, Bouche O, Lucas L, Hoeffel C (2009)
Imaging techniques to evaluate the response to treatment in oncology:
current standards and perspectives. Crit Rev Oncol Hematol. 72:217–238
34. Levine ZH, Pintar AL, Hagedorn JG, Fenimore CP, Heussel CP (2012)
Uncertainties in RECIST as a measure of volume for lung nodules and liver
tumours. Med Phys. 39:2628–2637
35. Hawnaur JM, Johnson RJ, Buckley CH, Tindall V, Isherwood I (1994) Staging,
volume estimation and assessment of nodal status in carcinoma of the
cervix: comparison of magnetic resonance imaging with surgical findings.
Clin Radiol. 49:443–452
36. Soutter WP, Hanoch J, D'Arcy T, Dina R, McIndoe GA, DeSouza NM (2004)
Pretreatment tumour volume measurement on high-resolution magnetic
resonance imaging as a predictor of survival in cervical cancer. BJOG 111:
741–747
37. Jiang Y, You K, Qiu X et al (2018) Tumour volume predicts local recurrence
in early rectal cancer treated with radical resection: a retrospective
observational study of 270 patients. Int J Surg 49:68–73
38. Tayyab M, Razack A, Sharma A, Gunn J, Hartley JE (2015) Correlation of
rectal tumour volumes with oncological outcomes for low rectal cancers:
does tumour size matter? Surg Today. 45:826–833
39. Wagenaar HC, Trimbos JB, Postema S et al (2001) Tumour diameter and
volume assessed by magnetic resonance imaging in the prediction of
outcome for invasive cervical cancer. Gynecol Oncol. 82:474–482
40. Lee JW, Lee SM, Yun M, Cho A (2016) Prognostic value of volumetric
parameters on staging and posttreatment FDG PET/CT in patients with
stage IV non-small cell lung cancer. Clin Nucl Med. 41:347–353
41. Kurtipek E, Cayci M, Duzgun N et al (2015) (18)F-FDG PET/CT mean SUV and
metabolic tumour volume for mean survival time in non-small cell lung
cancer. Clin Nucl Med. 40:459–463
42. Meignan M, Cottereau AS, Versari A et al (2016) Baseline metabolic tumour
volume predicts outcome in high-tumour-burden follicular lymphoma: a
pooled analysis of three multicenter studies. J Clin Oncol. 34:3618–3626
43. Meignan M, Itti E, Gallamini A, Younes A (2015) FDG PET/CT imaging as a
biomarker in lymphoma. Eur J Nucl Med Mol Imaging. 42:623–633
44. Kanoun S, Tal I, Berriolo-Riedinger A et al (2015) Influence of software tool
and methodological aspects of total metabolic tumour volume calculation
on baseline [18F]FDG PET to predict survival in Hodgkin lymphoma. PLoS
One. 10:e0140830
45. Kostakoglu L, Chauvie S (2018) Metabolic tumour volume metrics in
lymphoma. Semin Nucl Med. 48:50–66
46. Mori S, Oishi K, Faria AV, Miller MI (2013) Atlas-based neuroinformatics via
MRI: harnessing information from past clinical cases and quantitative image
analysis for patient care. Annu Rev Biomed Eng. 15:71–92
47. Cole JH, Poudel RPK, Tsagkrasoulis D et al (2017) Predicting brain age with
deep learning from raw imaging data results in a reliable and heritable
biomarker. Neuroimage. 163:115–124
48. Xu Y, Hosny A, Zeleznik R et al (2019) Deep learning predicts lung cancer
treatment response from serial medical imaging. Clin Cancer Res. 25:3266–3275
49. Ferraioli G, Wong VW, Castera L et al (2018) Liver ultrasound
elastography: an update to the world federation for ultrasound in
medicine and biology guidelines and recommendations. Ultrasound
Med Biol. 44:2419–2440
50. Lee SH, Chung J, Choi HY et al (2017) Evaluation of screening US-detected
breast masses by combined use of elastography and color doppler US with
B-Mode US in women with dense breasts: a multicenter prospective study.
Radiology. 285:660–669
51. Woo S, Suh CH, Kim SY, Cho JY, Kim SH (2017) Shear-wave elastography for
detection of prostate cancer: a systematic review and diagnostic meta-
analysis. AJR Am J Roentgenol. 209:806–814
52. Du LJ, He W, Cheng LG, Li S, Pan YS, Gao J (2016) Ultrasound shear wave
elastography in assessment of muscle stiffness in patients with Parkinson’s
disease: a primary observation. Clin Imaging. 40:1075–1080
53. Ramnarine KV, Garrard JW, Kanber B, Nduwayo S, Hartshorne TC, Robinson
TG (2014) Shear wave elastography imaging of carotid plaques: feasible,
reproducible and of clinical potential. Cardiovasc Ultrasound. 12:49
54. Dori A, Abbasi H, Zaidman CM (2016) Intramuscular blood flow quantification
with power doppler ultrasonography. Muscle Nerve. 54:872–878
55. Regan EA, Hokanson JE, Murphy JR et al (2010) Genetic epidemiology of
COPD (COPDGene) study design. COPD. 7:32–43
56. Sieren JP, Newell JD Jr, Barr RG et al (2016) SPIROMICS protocol for
multicenter quantitative computed tomography to phenotype the lungs.
Am J Respir Crit Care Med. 194:794–806
57. Keene JD, Jacobson S, Kechris K et al (2017) Biomarkers predictive of
exacerbations in the SPIROMICS and COPDGene cohorts. Am J Respir Crit
Care Med. 195:473–481
58. Andrade J, Schwarz M, Collard HR et al (2015) The Idiopathic Pulmonary
Fibrosis Clinical Research Network (IPFnet): diagnostic and adjudication
processes. Chest. 148:1034–1042
59. Washko GR, Diaz AA, Kim V et al (2014) Computed tomographic measures
of airway morphology in smokers and never-smoking normals. J Appl
Physiol (1985). 116:668–673
60. Jarjour NN, Erzurum SC, Bleecker ER et al (2012) Severe asthma: lessons
learned from the National Heart, Lung, and Blood Institute Severe Asthma
Research Program. Am J Respir Crit Care Med. 185:356–362
61. Schuhmann M, Raffy P, Yin Y et al (2015) Computed tomography predictors of
response to endobronchial valve lung reduction treatment. Comparison with
Chartis. Am J Respir Crit Care Med. 191:767–774
62. Van Der Molen MC, Klooster K, Hartman JE, Slebos DJ (2018) Lung volume
reduction with endobronchial valves in patients with emphysema. Expert
Rev Med Devices. 15:847–857
63. Salisbury ML, Lynch DA, van Beek EJ et al (2017) Idiopathic pulmonary
fibrosis: the association between the adaptive multiple features method
and fibrosis outcomes. Am J Respir Crit Care Med. 195:921–929
64. Goyal M, Menon BK, Derdeyn CP (2013) Perfusion imaging in acute
ischaemic stroke: let us improve the science before changing clinical
practice. Radiology. 266:16–21
65. Guo J, Wang C, Chan KS et al (2016) A controlled statistical study to assess
measurement variability as a function of test object position and
configuration for automated surveillance in a multicenter longitudinal
COPD study (SPIROMICS). Med Phys. 43:2598
66. Rodriguez A, Ranallo FN, Judy PF, Fain SB (2017) The effects of iterative
reconstruction and kernel selection on quantitative computed tomography
measures of lung density. Med Phys. 44:2267–2280
67. Al-Mallah MH (2018) Coronary artery calcium scoring: do we need more
prognostic data prior to adoption in clinical practice? JACC Cardiovasc
Imaging. 11:1807–1809
68. Hoffmann U, Ferencik M, Udelson JE et al (2017) Prognostic value of
noninvasive cardiovascular testing in patients with stable chest pain:
insights from the PROMISE trial (Prospective Multicenter Imaging Study for
Evaluation of Chest Pain). Circulation. 135:2320–2332
69. Newby DE, Adamson PD, Berry C et al (2018) Coronary CT angiography and
5-year risk of myocardial infarction. N Engl J Med. 379:924–933
70. Altenbernd J, Wetter A, Umutlu L et al (2016) Dual-energy computed
tomography for evaluation of pulmonary nodules with emphasis on
metastatic lesions. Acta Radiol 57:437–443
71. Lennartz S, Le Blanc M, Zopfs D et al (2019) Dual-energy CT derived iodine
maps: use in assessing pleural carcinomatosis. Radiology. 290:796–804
72. Barker P, Golay X, Zaharchuk G (2013) Clinical perfusion MRI: techniques and
applications. Cambridge University Press.
deSouza et al. Insights into Imaging           (2019) 10:87 Page 13 of 16
73. Bittencourt LK, de Hollanda ES, de Oliveira RV (2016) Multiparametric MR
imaging for detection and locoregional staging of prostate cancer. Top
Magn Reson Imaging. 25:109–117
74. Lopci E, Franzese C, Grimaldi M et al (2015) Imaging biomarkers in primary
brain tumours. Eur J Nucl Med Mol Imaging. 42:597–612
75. Bollineni VR, Kramer G, Liu Y, Melidis C, deSouza NM (2015) A literature
review of the association between diffusion-weighted MRI derived apparent
diffusion coefficient and tumour aggressiveness in pelvic cancer. Cancer
Treat Rev 41:496–502
76. Galban CJ, Hoff BA, Chenevert TL, Ross BD (2017) Diffusion MRI in early
cancer therapeutic response assessment. NMR Biomed. 30
77. Shukla-Dave A, Obuchowski NA, Chenevert TL et al (2018) Quantitative
imaging biomarkers alliance (QIBA) recommendations for improved
precision of DWI and DCE-MRI derived biomarkers in multicenter oncology
trials. J Magn Reson Imaging. 49:e101–e121
78. Zeng Q, Shi F, Zhang J, Ling C, Dong F, Jiang B (2018) A modified tri-exponential
model for multi-b-value diffusion-weighted imaging: a method to detect the
strictly diffusion-limited compartment in brain. Front Neurosci 12:102
79. Langkilde F, Kobus T, Fedorov A et al (2018) Evaluation of fitting models for
prostate tissue characterization using extended-range b-factor diffusion-
weighted imaging. Magn Reson Med. 79:2346–2358
80. Winfield JM, Tunariu N, Rata M et al (2017) Extracranial soft-tissue tumours:
repeatability of apparent diffusion coefficient estimates from diffusion-
weighted MR imaging. Radiology 284:88–99
81. Taylor AJ, Salerno M, Dharmakumar R, Jerosch-Herold M (2016) T1 mapping:
basic techniques and clinical applications. JACC Cardiovasc Imaging. 9:67–81
82. Toussaint M, Gilles RJ, Azzabou N et al (2015) Characterization of benign
myocarditis using quantitative delayed-enhancement imaging based on
Molli T1 mapping. Medicine (Baltimore). 94:e1868
83. Jurcoane A, Wagner M, Schmidt C et al (2013) Within-lesion differences in
quantitative MRI parameters predict contrast enhancement in multiple
sclerosis. J Magn Reson Imaging. 38:1454–1461
84. Katsube T, Okada M, Kumano S et al (2011) Estimation of liver function
using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance
imaging. Invest Radiol. 46:277–283
85. Mozes FE, Tunnicliffe EM, Moolla A et al (2018) Mapping tissue water T1 in
the liver using the MOLLI T1 method in the presence of fat, iron and B0
inhomogeneity. NMR Biomed e4030
86. Adam SZ, Nikolaidis P, Horowitz JM et al (2016) Chemical shift MR imaging of the
adrenal gland: principles, pitfalls, and applications. Radiographics. 36:414–432
87. Yang L, Ding Y, Rao S et al (2017) Staging liver fibrosis in chronic hepatitis B
with T1 relaxation time index on gadoxetic acid-enhanced MRI: comparison
with aspartate aminotransferase-to-platelet ratio index and FIB-4. J Magn
Reson Imaging 45:1186–1194
88. McDonald N, Eddowes PJ (2018) Multiparametric magnetic resonance
imaging for quantitation of liver disease: a two-centre cross-sectional
observational study. Sci Rep 8:9189
89. Serai SD, Obuchowski NA, Venkatesh SK et al (2017) Repeatability of MR
elastography of liver: a meta-analysis. Radiology. 285:92–100
90. Tietze A, Blicher J, Mikkelsen IK et al (2014) Assessment of ischemic
penumbra in patients with hyperacute stroke using amide proton transfer
(APT) chemical exchange saturation transfer (CEST) MRI. NMR Biomed. 27:
163–174
91. Donahue MJ, Donahue PC, Rane S et al (2016) Assessment of lymphatic
impairment and interstitial protein accumulation in patients with breast
cancer treatment-related lymphedema using CEST MRI. Magn Reson Med.
75:345–355
92. Krishnamoorthy G, Nanga RPR, Bagga P, Hariharan H, Reddy R (2017) High
quality three-dimensional gagCEST imaging of in vivo human knee cartilage
at 7 Tesla. Magn Reson Med. 77:1866–1873
93. Lindeman LR, Randtke EA, High RA, Jones KM, Howison CM, Pagel MD
(2018) A comparison of exogenous and endogenous CEST MRI methods for
evaluating in vivo pH. Magn Reson Med. 79:2766–2772
94. David S, Visvikis D, Roux C, Hatt M (2011) Multi-observation PET image
analysis for patient follow-up quantitation and therapy assessment. Phys
Med Biol. 56:5771–5788
95. McDonald JE, Kessler MM, Gardner MW et al (2017) Assessment of total
lesion glycolysis by (18)F FDG PET/CT significantly improves prognostic
value of GEP and ISS in myeloma. Clin Cancer Res 23:1981–1987
96. Boellaard R (2009) Standards for PET image acquisition and quantitative
data analysis. J Nucl Med 50(Suppl 1):11s–20s
97. Boellaard R, O'Doherty MJ, Weber WA et al (2010) FDG PET and PET/CT:
EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl
Med Mol Imaging. 37:181–200
98. Kaalep A, Sera T, Rijnsdorp S et al (2018) Feasibility of state of the art PET/CT
systems performance harmonisation. Eur J Nucl Med Mol Imaging. 45:1344–
1361
99. Hoffmann R, von Bardeleben S, ten Cate F et al (2005) Assessment of
systolic left ventricular function: a multi-centre comparison of
cineventriculography, cardiac magnetic resonance imaging, unenhanced
and contrast-enhanced echocardiography. Eur Heart J. 26:607–616
100. Donal E, Delgado V, Magne J et al (2017) Rational and design of EuroCRT:
an international observational study on multi-modality imaging and cardiac
resynchronization therapy. Eur Heart J Cardiovasc Imaging. 18:1120–1127
101. de Amorim Paiva CC, de Mello Junior CF, Guimaraes Filho HA et al (2014)
Reproducibility of renal volume measurement in adults using 3-dimensional
sonography. J Ultrasound Med 33:431–435
102. Janki S1, Kimenai HJAN, Dijkshoorn ML, Looman CWN, Dwarkasing RS,
IJzermans JNM (2018) Validation of ultrasonographic kidney volume
measurements: a reliable imaging modality. Exp Clin Transplant 16:16–22
103. Di Leo G, Di Terlizzi F, Flor N, Morganti A, Sardanelli F (2011) Measurement
of renal volume using respiratory-gated MRI in subjects without known
kidney disease: intraobserver, interobserver, and interstudy reproducibility.
Eur J Radiol. 80:e212–e216
104. Veyrieres JB, Albarel F, Lombard JV et al (2012) A threshold value in Shear
Wave elastography to rule out malignant thyroid nodules: a reality? Eur J
Radiol. 81:3965–3972
105. Chang CY, Chang SJ, Chang SC, Yuan MK (2013) The value of positron
emission tomography in early detection of lung cancer in high-risk
population: a systematic review. Clin Respir J. 7:1–6
106. Martinez CH, Chen YH, Westgate PM et al (2012) Relationship between
quantitative CT metrics and health status and BODE in chronic obstructive
pulmonary disease. Thorax. 67:399–406
107. Lynch DA, Moore CM, Wilson C et al (2018) CT-based visual classification of
emphysema: association with mortality in the COPDGene study. Radiology.
288:859–866
108. Jacob J, Bartholmai BJ, Rajagopalan S et al (2017) Mortality prediction in
idiopathic pulmonary fibrosis: evaluation of computer-based CT analysis
with conventional severity measures. Eur Respir J. 49
109. Jovin TG, Saver JL, Ribo M et al (2017) Diffusion-weighted imaging or
computerized tomography perfusion assessment with clinical mismatch in the
triage of wake up and late presenting strokes undergoing neurointervention
with Trevo (DAWN) trial methods. Int J Stroke. 12:641–652
110. van Riel SJ, Ciompi F, Jacobs C et al (2017) Malignancy risk estimation of
screen-detected nodules at baseline CT: comparison of the PanCan model,
Lung-RADS and NCCN guidelines. Eur Radiol. 27:4019–4029
111. Heuvelmans MA, Walter JE, Vliegenthart R et al (2018) Disagreement of
diameter and volume measurements for pulmonary nodule size estimation
in CT lung cancer screening. Thorax. 73:779–781
112. Matoba M, Tsuji H, Shimode Y, Nagata H, Tonami H (2018) Diagnostic
performance of adaptive 4D volume perfusion CT for detecting metastatic
cervical lymph nodes in head and neck squamous cell carcinoma. AJR Am J
Roentgenology. 211:1106–1111
113. Zhang D, Xu A (2017) Application of dual-source CT perfusion imaging and
MRI for the diagnosis of primary liver cancer. Oncol Lett. 14:5753–5758
114. Timmers JM, van Doorne-Nagtegaal HJ, Zonderland HM et al (2012) The
Breast Imaging Reporting and Data System (BI-RADS) in the Dutch breast
cancer screening programme: its role as an assessment and stratification
tool. Eur Radiol 22:1717–1723
115. Zhang L, Tang M, Chen S, Lei X, Zhang X, Huan Y (2017) A meta-analysis of
use of Prostate Imaging Reporting and Data System Version 2 (PI-RADS V2)
with multiparametric MR imaging for the detection of prostate cancer. Eur
Radiol. 27:5204–5214
116. van der Pol CB, Lim CS, Sirlin CB et al (2019) Accuracy of the liver imaging
reporting and data system in computed tomography and magnetic
resonance image analysis of hepatocellular carcinoma or overall
malignancy-a systematic review. Gastroenterology. 156:976–986
117. deSouza NM, Winfield JM, Waterton JC et al (2018) Implementing diffusion-
weighted MRI for body imaging in prospective multicentre trials: current
considerations and future perspectives. Eur Radiol 28:1118–1131
118. Hu Y, Tang H, Li H et al (2018) Assessment of different mathematical
models for diffusion-weighted imaging as quantitative biomarkers for
deSouza et al. Insights into Imaging           (2019) 10:87 Page 14 of 16
differentiating benign from malignant solid hepatic lesions. Cancer Med.
https://doi.org/10.1002/cam4.1535. [Epub ahead of print]
119. Bao J, Wang X, Hu C, Hou J, Dong F, Guo L (2017) Differentiation of
prostate cancer lesions in the transition zone by diffusion-weighted MRI. Eur
J Radiol Open. 4:123–128
120. Nael K, Bauer AH, Hormigo A et al (2018) Multiparametric MRI for
differentiation of radiation necrosis from recurrent tumour in patients with
treated glioblastoma. AJR Am J Roentgenol 210:18–23
121. Bastiaannet E, Groen H, Jager PL et al (2004) The value of FDG-PET in the
detection, grading and response to therapy of soft tissue and bone sarcomas;
a systematic review and meta-analysis. Cancer Treat Rev. 30:83–101
122. van Dijk LV, Brouwer CL, van der Laan HP et al (2017) Geometric image
biomarker changes of the parotid gland are associated with late xerostomia.
Int J Radiat Oncol Biol Phys. 99:1101–1110
123. Lu SJ, Gnanasegaran G, Buscombe J, Navalkissoor S (2013) Single photon
emission computed tomography/computed tomography in the evaluation
of neuroendocrine tumours: a review of the literature. Nucl Med Commun
34:98–107
124. Ambrosini V, Campana D, Tomassetti P, Fanti S (2012) 68Ga-labelled
peptides for diagnosis of gastroenteropancreatic NET. Eur J Nucl Med Mol
Imaging. 39(Suppl 1):S52–S60
125. Maxwell JE, Howe JR (2015) Imaging in neuroendocrine tumours: an update
for the clinician. Int J Endocr Oncol. 2:159–168
126. Gabriel M, Decristoforo C, Kendler D et al (2007) 68Ga-DOTA-Tyr3-octreotide
PET in neuroendocrine tumours: comparison with somatostatin receptor
scintigraphy and CT. J Nuclear Med 48:508–518
127. Park SY, Zacharias C, Harrison C et al (2018) Gallium 68 PSMA-11 PET/MR
imaging in patients with intermediate- or high-risk prostate cancer.
Radiology 288:495–505
128. Lambin P, Rios-Velazquez E, Leijenaar R et al (2012) Radiomics: extracting
more information from medical images using advanced feature analysis. Eur
J Cancer 48:441–446
129. Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: images are more than
pictures, they are data. Radiology. 278:563–577
130. Aerts HJ, Velazquez ER, Leijenaar RT et al (2014) Decoding tumour
phenotype by noninvasive imaging using a quantitative radiomics
approach. Nat Commun 5:4006
131. Yip SS, Aerts HJ (2016) Applications and limitations of radiomics. Phys Med
Biol. 61:R150–R166
132. O'Connor JP, Rose CJ, Waterton JC, Carano RA, Parker GJ, Jackson A (2015)
Imaging intratumor heterogeneity: role in therapy response, resistance, and
clinical outcome. Clin Cancer Res 21:249–257
133. Drukker K, Giger ML, Joe BN (2018) Combined benefit of quantitative
threecompartment breast image analysis and mammography radiomics in the
classification of breast masses in a clinical data set Radiology. 290:621–628
134. Lu M, Zhan X (2018) The crucial role of multiomic approach in cancer
research and clinically relevant outcomes. EPMA J 9:77–102
135. Zhao B, Tan Y, Tsai WY et al (2016) Reproducibility of radiomics for
deciphering tumour phenotype with imaging. Sci Rep. 6:23428
136. Peerlings J, Woodruff H, Winfield J et al (2019) Stability of radiomics features
in apparent diffusion coefficient maps from a multi-centre test-retest trial.
Sci Rep 9(1):4800
137. Kanis JA, Harvey NC, Cooper C, Johansson H, Oden A, McCloskey EV (2016)
A systematic review of intervention thresholds based on FRAX : a report
prepared for the National Osteoporosis Guideline Group and the
International Osteoporosis Foundation. Arch Osteoporos 11:25
138. Cho I, Al’Aref SJ, Berger A et al (2018) Prognostic value of coronary
computed tomographic angiography findings in asymptomatic individuals:
a 6-year follow-up from the prospective multicentre international CONFIRM
study. Eur Heart J. 39:934–941
139. Dweck MR, Chow MW, Joshi NV et al (2012) Coronary arterial 18F-sodium fluoride
uptake: a novel marker of plaque biology. J Am Coll Cardiol 59:1539–1548
140. Pawade TA, Cartlidge TR, Jenkins WS et al (2016) Optimization and
reproducibility of aortic valve 18F-fluoride positron emission tomography in
patients with aortic stenosis. Circ Cardiovasc imaging. 9
141. Dweck MR, Jenkins WS, Vesey AT et al (2014) 18F-sodium fluoride uptake is
a marker of active calcification and disease progression in patients with
aortic stenosis. Circ Cardiovasc Imaging. 7:371–378
142. Joshi NV, Vesey AT, Williams MC et al (2014) 18F-fluoride positron emission
tomography for identification of ruptured and high-risk coronary
atherosclerotic plaques: a prospective clinical trial. Lancet 383:705–713
143. Forsythe RO, Dweck MR, McBride OMB et al (2018) 18F-sodium fluoride
uptake in abdominal aortic aneurysms: the SoFIA3 study. J Am Coll Cardiol.
71:513–523
144. Mesaros S, Rocca M, Sormani M et al (2010) Bimonthly assessment of
magnetisation transfer magnetic resonance imaging parameters in multiple
sclerosis: a 14-month, multicentre, follow-up study. Mult Scler 16:325–331
145. Agosta F, Rovaris M, Pagani E, Sormani MP, Comi G, Filippi M (2006)
Magnetisation transfer MRI metrics predict the accumulation of disability 8
years later in patients with multiple sclerosis. Brain 129:2620–2627
146. Rovaris M, Agosta F, Sormani MP et al (2003) Conventional and
magnetisation transfer MRI predictors of clinical multiple sclerosis evolution:
a medium-term follow-up study. Brain 126:2323–2332
147. Deantonio L, Caroli A, Puta E et al (2018) Does baseline [18F] FDG-PET/CT
correlate with tumour staging, response after neoadjuvant chemoradiotherapy,
and prognosis in patients with rectal cancer? Radiat Oncol 13:211
148. Pan L, Gu P, Huang G, Xue H, Wu S (2009) Prognostic significance of SUV on
PET/CT in patients with esophageal cancer: a systematic review and meta-
analysis. European journal of gastroenterology & hepatology. 21:1008–1015
149. Lewis S, Besa C, Wagner M et al (2018) Prediction of the histopathologic
findings of intrahepatic cholangiocarcinoma: qualitative and quantitative
assessment of diffusion-weighted imaging. Eur Radiol. 28:2047–2057
150. Wang YT, Li YC, Yin LL, Pu H (2016) Can diffusion-weighted magnetic
resonance imaging predict survival in patients with cervical cancer? A meta-
analysis. Eur J Radiol. 85:2174–2181
151. Yu AC, Badve C, Ponsky LE et al (2017) Development of a combined MR
fingerprinting and diffusion examination for prostate cancer. Radiology. 283:
729–738
152. Delgado AF, Delgado AF (2017) Discrimination between glioma grades II
and III using dynamic susceptibility perfusion MRI: a meta-analysis. AJNR Am
J Neuroradiol 38:1348–1355
153. Su C, Liu C, Zhao L et al (2017) Amide proton transfer imaging allows
detection of glioma grades and tumor proliferation: comparison with Ki-67
expression and proton MR spectroscopy imaging. AJNR Am J Neuroradiol.
38(9):1702–1709
154. Hayano K, Shuto K, Koda K, Yanagawa N, Okazumi S, Matsubara H (2009)
Quantitative measurement of blood flow using perfusion CT for assessing
clinicopathologic features and prognosis in patients with rectal cancer. Dis
Colon Rectum. 52:1624–1629
155. Win T, Miles KA, Janes SM et al (2013) Tumour heterogeneity and
permeability as measured on the CT component of PET/CT predict survival
in patients with non-small cell lung cancer. Clinical cancer research : an
official journal of the American Association for Cancer Research. 19:3591–
3599
156. Lund KV, Simonsen TG, Kristensen GB, Rofstad EK (2017) Pretreatment late-
phase DCE-MRI predicts outcome in locally advanced cervix cancer. Acta
Oncol 56:675–681
157. Fasmer KE, Bjornerud A, Ytre-Hauge S (2018) Preoperative quantitative
dynamic contrast-enhanced MRI and diffusion-weighted imaging predict
aggressive disease in endometrial cancer. Acta Radiol 59:1010–1017
158. Yu J, Xu Q, Huang DY et al (2017) Prognostic aspects of dynamic contrast-
enhanced magnetic resonance imaging in synchronous distant metastatic
rectal cancer. Eur Radiol. 27:1840–1847
159. Wilson R, Devaraj A (2017) Radiomics of pulmonary nodules and lung
cancer. Transl Lung Cancer Res. 6:86–91
160. Lee JW, Lee SM (2018) Radiomics in oncological PET/CT: clinical
applications. Nucl Med Mol Imaging. 52:170–189
161. Kumar V, Gu Y, Basu S et al (2012) Radiomics: the process and the
challenges. Magn Reson imaging. 30:1234–1248
162. Zhang Y, Oikonomou A, Wong A, Haider MA, Khalvati F (2017) Radiomics-
based prognosis analysis for non-small cell lung cancer. Sci Rep. 7:46349
163. Huang YQ, Liang CH, He L et al (2016) Development and validation of a
radiomics nomogram for preoperative prediction of lymph node metastasis
in colorectal cancer. J Clin Oncol. 34:2157–2164
164. Goldin JG, Kim GHJ, Tseng CH et al (2018) Longitudinal changes in
quantitative interstitial lung disease on computed tomography after
immunosuppression in the Scleroderma Lung Study II. Ann Am Thorac Soc.
15:1286–1295
165. Peacock AJ, Crawley S, McLure L et al (2014) Changes in right ventricular
function measured by cardiac magnetic resonance imaging in patients
receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR
study. Circ Cardiovasc Imaging. 7:107–114
deSouza et al. Insights into Imaging           (2019) 10:87 Page 15 of 16
166. Steinhoff G, Nesteruk J, Wolfien M et al (2017) Cardiac function
improvement and bone marrow response -: outcome analysis of the
randomized PERFECT phase III clinical trial of intramyocardial CD133+
application after myocardial infarction. EBioMedicine 22:208–224.
167. Schwartz LH, Seymour L, Litiere S et al (2016) RECIST 1.1 - standardisation
and disease-specific adaptations: perspectives from the RECIST Working
Group. Eur J Cancer 62:138–145
168. Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST:
evolving considerations for PET response criteria in solid tumours. J Nucl
Med 50(Suppl 1):122s–150s
169. Sormani MP, De Stefano N (2013) Defining and scoring response to IFN-
beta in multiple sclerosis. Nat Rev Neurol. 9:504–512
170. Ostergaard M, Bird P, Gandjbakhch F et al (2015) The OMERACT MRI in
arthritis working group - update on status and future research priorities. J
Rheumatol. 42:2470–2472
171. Patel P, Baradaran H, Delgado D et al (2017) MR perfusion-weighted
imaging in the evaluation of high-grade gliomas after treatment: a
systematic review and meta-analysis. Neuro Oncol. 19:118–127
172. van Dijken BRJ, van Laar PJ, Holtman GA, van der Hoorn A (2017) Diagnostic
accuracy of magnetic resonance imaging techniques for treatment
response evaluation in patients with high-grade glioma, a systematic review
and meta-analysis. Eur Radiol. 27:4129–4144
173. Aide N, Lasnon C, Veit-Haibach P, Sera T, Sattler B, Boellaard R (2017) EANM/
EARL harmonization strategies in PET quantification: from daily practice to
multicentre oncological studies. Eur J Nucl Med Mol Imaging. 44:17–31
174. Maffione AM, Marzola MC, Capirci C, Colletti PM, Rubello D (2015) Value of
18F-FDG PET for predicting response to neoadjuvant therapy in rectal
cancer: systematic review and meta-analysis. AJR Am J Roentgenology. 204:
1261–1268
175. Martens RM, Noij DP, Ali M et al (2019) Functional imaging early during
(chemo)radiotherapy for response prediction in head and neck squamous
cell carcinoma; a systematic review. Oral Oncol. 88:75–83
176. Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial
evaluation, staging, and response assessment of Hodgkin and non-Hodgkin
lymphoma: the Lugano classification. J Clin Oncol 32:3059–3068
177. Younes A, Hilden P, Coiffier B et al (2017) International Working Group consensus
response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 28:1436–1447
178. Dalm SU, Verzijlbergen JF, De Jong M (2017) Review: receptor targeted
nuclear imaging of breast cancer. Int J Mol Sci 18
179. Bakht MK, Oh SW, Youn H, Cheon GJ, Kwak C, Kang KW (2017) Influence of
androgen deprivation therapy on the uptake of PSMA-targeted agents:
emerging opportunities and challenges. Nucl Med Mol Imaging 51:202–211
180. Hotker AM, Tarlinton L, Mazaheri Y et al (2016) Multiparametric MRI in the
assessment of response of rectal cancer to neoadjuvant chemoradiotherapy:
a comparison of morphological, volumetric and functional MRI parameters.
Eur Radiol. 26:4303–4312
181. Partridge SC, Zhang Z, Newitt DC et al (2018) Diffusion-weighted MRI
findings predict pathologic response in neoadjuvant treatment of breast
cancer: the ACRIN 6698 Multicenter Trial. Radiology 289:618–627.
182. Hayano K, Okazumi S, Shuto K et al (2007) Perfusion CT can predict the
response to chemoradiation therapy and survival in esophageal squamous
cell carcinoma: initial clinical results. Oncol Rep. 18:901–908
183. O'Connor JP, Jackson A, Parker GJ, Roberts C, Jayson GC (2012) Dynamic
contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev
Clin Oncol. 9:167–177
184. Choi H, Charnsangavej C, Faria SC et al (2007) Correlation of computed
tomography and positron emission tomography in patients with metastatic
gastrointestinal stromal tumour treated at a single institution with imatinib
mesylate: proposal of new computed tomography response criteria. J Clin
Oncol 25:1753–1759
185. El Alaoui-Lasmaili K, Faivre B (2018) Antiangiogenic therapy: markers of
response, “normalization” and resistance. Crit Rev Oncol Hematol. 128:
118–129
186. Sheikhbahaei S, Mena E, Yanamadala A et al (2017) The value of FDG PET/
CT in treatment response assessment, follow-up, and surveillance of lung
cancer. AJR Am J Roentgenol. 208:420–433
187. Goense L, van Rossum PS, Reitsma JB et al (2015) Diagnostic performance
of 18F-FDG PET and PET/CT for the detection of recurrent esophageal
cancer after treatment with curative intent: a systematic review and meta-
analysis. J Nucl Med 56:995–1002
188. Sullivan DC, Obuchowski NA, Kessler LG et al (2015) Metrology standards for
quantitative imaging biomarkers. Radiology. 277:813–825
189. Waterton JC, Pylkkanen L (2012) Qualification of imaging biomarkers for
oncology drug development. Eur J Cancer 48:409–415
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
deSouza et al. Insights into Imaging           (2019) 10:87 Page 16 of 16
